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Abstract
Introduction: Recent evidence suggests that choice of fluid used for resuscitation may influence mortality in
critically ill patients.
Methods: We conducted a cross-sectional study in 391 intensive care units across 25 countries to describe the
types of fluids administered during resuscitation episodes. We used generalized estimating equations to examine
the association between patient, prescriber and geographic factors and the type of fluid administered (classified as
crystalloid, colloid or blood products).
Results: During the 24-hour study period, 1,955 of 5,274 (37.1%) patients received resuscitation fluid during 4,488
resuscitation episodes. The main indications for administering crystalloid or colloid were impaired perfusion (1,526/
3,419 (44.6%) of episodes), or to correct abnormal vital signs (1,189/3,419 (34.8%)). Overall, colloid was administered
to more patients (1,234 (23.4%) versus 782 (14.8%)) and during more episodes (2,173 (48.4%) versus 1,468 (32.7%))
than crystalloid. After adjusting for patient and prescriber characteristics, practice varied significantly between
countries with country being a strong independent determinant of the type of fluid prescribed. Compared to
Canada where crystalloid, colloid and blood products were administered in 35.5%, 40.6% and 28.3% of resuscitation
episodes respectively, odds ratios for the prescription of crystalloid in China, Great Britain and New Zealand were
0.46 (95% confidence interval (CI) 0.30 to 0.69), 0.18 (0.10 to 0.32) and 3.43 (1.71 to 6.84) respectively; odds ratios
for the prescription of colloid in China, Great Britain and New Zealand were 1.72 (1.20 to 2.47), 4.72 (2.99 to 7.44)
and 0.39 (0.21 to 0.74) respectively. In contrast, choice of fluid was not influenced by measures of illness severity
(for example, Acute Physiology and Chronic Health Evaluation (APACHE) II score).
Conclusions: Administration of resuscitation fluid is a common intervention in intensive care units and choice of
fluid varies markedly between countries. Although colloid solutions are more expensive and may possibly be
harmful in some patients, they were administered to more patients and during more resuscitation episodes than
crystalloids were.
Introduction
Administration of intravenous fluid is one of the most
common interventions in the management of patients in
intensive care units (ICUs). Despite this, there is limited
high quality information to guide clinicians in deciding
when fluid resuscitation may be indicated and what type
of fluid to prescribe [1-3]. Reports from clinicians sug-
gest that the type of fluid used for resuscitation varies
widely [4-6] but there is little evidence regarding what
fluids are administered and the factors that influence
the type of fluid prescribed. We conducted an interna-
tional cross-sectional study of intensive care units to
examine these issues.
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Design and setting
A total of 391 intensive care units (ICUs) from 25 coun-
tries contributed data to the study (hereafter referred to
as contributing ICUs). The contributing ICUs were
recruited through convenience sampling using the per-
sonal contacts of the investigators and by contacting the
leaders of critical care research networks. All institutions
that obtained ethical approval according to the local
requirements were included. For the purposes of this
observational study, as there was no deviation from rou-
tine medical care, ethical board approval was either
waved or expedited at all sites and individual patient
informed consent was not required. Data were collected
for all patients present in the contributing ICUs for all
or part of a single 24-hour study day in 2007. Depend-
ing on local logistic considerations each contributing
ICU chose the 18 or 25 April, 16 May, 20 June or 11
July as their study day.
Participants and data collection
Data were collected on a standard data collection form
(see Additional file 1) and this was returned to the
study co-ordinating centre for entry into the study data-
base. Data were checked against pre-specified range lim-
its and any queries were resolved with the study sites.
For each patient, information was collected on their sex,
age, ICU admission date, admission source and diagno-
sis (based on the Acute Physiology and Chronic Health
Evaluation (APACHE) II [7] diagnosis codes) and
whether resuscitation fluid or blood products were pre-
scribed. An episode of fluid resuscitation was defined as
an hour during which either a bolus of crystalloid or
colloid; a crystalloid infusion of 5 ml/kg/hr or greater; a
continuous infusion of colloid at any dose; or any
volume of whole blood, packed red blood cells, fresh
frozen plasma or platelets was given.
For patients who received at least one episode of fluid
resuscitation during the study period additional informa-
tion was collected from the patient’s medical record.
This included the patient’sw e i g h t ,A P A C H EI Is c o r e
[7], the presence of trauma as the primary ICU admis-
sion diagnosis, and based on standard definitions, the
presence of traumatic brain injury [8], severe sepsis [9]
or acute respiratory distress syndrome [10]. For each
episode of fluid resuscitation the types of fluids and
volumes infused, cardiovascular and respiratory compo-
nents of the Sequential Organ Failure Assessment
(SOFA) score [11], clinical signs (heart rate, mean arter-
ial pressure, central venous pressure), most recent
laboratory measures (haemoglobin, creatinine, bilirubin,
lactate, and albumin concentrations), urine output and
total fluid output in the previous complete hour, use of
renal replacement therapy and mechanical ventilation
were recorded. The type of fluid given for resuscitation
was classified into crystalloid, colloid (with colloid sub-
classification as albumin, starch, gelatin or dextran solu-
tions), or blood products (whole blood, packed cells,
platelets or fresh frozen plasma) as indicated on the
standard data collection form (Additional file 1). The
indication for the fluid, the specialty and seniority of the
fluid prescriber, and the type of fluid prescribed was
recorded by the bedside nurse at the time of the resusci-
tation episode. For episodes where more than one indi-
cation for fluid resuscitation was provided, these were
classified according to a predetermined hierarchy (see
Additional File 2). Data on mortality or discharge at 28
days following ICU admission were also collected to
characterise the study population.
Statistical analysis
Patients aged less than 16 years were excluded from
analyses. As more than one type of fluid could have
been administered during one fluid resuscitation epi-
sode, where proportions of episodes are given they may
add to more than 100%; also separate analyses were
conducted for each type of fluid, that is, crystalloid
given or not, colloid given or not, blood product given
or not. The association between a patient’s demographic
and clinical characteristics and the type of fluid adminis-
tered were analysed using generalized estimating equa-
tions. Initially each factor of interest was examined
separately to determine if there was an association with
the type of fluid administered. Factors found to have a
predetermined level of association (P <0 . 1 )w i t ht h e
administration of crystalloid, colloid or blood product
were then included in multivariate analyses. In the mul-
tivariate analysis, a conservative approach was taken and
associations were considered significant if P < 0.01.
In analyses, for categorical data with no natural order,
the reference group was selected based on the category
with the greatest number of observations except for
country, where Canada was selected because the pattern
of fluid use in Canada most closely resembled that of all
the contributing ICUs combined. Countries (or terri-
tories) with less than 100 episodes of resuscitation were
combined into two categories, ‘other European coun-
tries’ (Iceland, Republic of Ireland and Northern Ireland,
Norway and Portugal) and ‘other countries’ (Brazil,
India, Japan, Saudi Arabia, Singapore and United Arab
Emirates). Analyses were conducted using STATA 9.2
statistical software (Stata Corp LP, College Station,
Texas, USA).
Results
After excluding 62 patients aged less than 16 years or of
unknown age, a total of 5,274 patients were included.
Table 1 shows the contributing countries and within
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and fluid resuscitation episodes. Overall 37.1% (1,955) of
patients received fluid resuscitation during the 24-hour
study period. This percentage was higher in patients for
whom the study period coincided with their admission
date to ICU; specifically 55% and 40% of patients who
were surveyed on respectively Day 0 or Day 1 in the
ICU received fluid resuscitation (Figure 1). Of the
patients who received fluid, 848 (43.4%) received fluid in
one hour only, 495 (25.3%) in two separate hours and
612 (31.3%) in three separate hours or more. Among
those receiving fluid, the median number of hours
where fluid was administered was two (mean two, inter-
quartile range one to three).
Figures 2 and 3 show by country the proportion of
fluid resuscitation episodes given as crystalloid, colloid
and blood product, and the types of colloid as a propor-
tion of all episodes where colloid was given, respectively.
Overall crystalloid was administered during 33% of
resuscitation episodes, colloid during 48% of episodes
and blood products during 28%. Between countries the
percentage of episodes where crystalloid was adminis-
tered ranged from 9 to 58%, colloid from 13 to 76% and
blood products from 18 to 42%. The type of colloid
used for fluid resuscitation in the contributing ICUs also
differed between countries (Figure 3); overall starch was
administered in 44% of colloid resuscitation episodes,
albumin in 30%, gelatin in 25% and dextran in 3%.
The characteristics of the 1,955 patients who received
fluid resuscitation during the study are shown in Table
2. Of the 4,488 episodes of fluid resuscitation, 39.2%
were for the indication of impaired perfusion or low car-
diac output. The majority of other fluid resuscitation
episodes were for abnormal vital signs in the absence of
impaired perfusion (28.5%) or for anaemia, bleeding or
coagulopathy (18.5%). Considering only episodes where
crystalloid or colloid were administered (n =3 , 4 1 9 ) ,t h e
main indications were impaired perfusion or low cardiac
output (44.6%), or to correct abnormal vital signs in the
absence of impaired perfusion or low cardiac output
(34.8%).
The patient characteristics, clinical signs and prescri-
ber factors associated with administration of crystalloid,
colloid or blood products, are shown by patient and by
episode of fluid resuscitation in Tables 3 and 4 respec-
tively. After adjusting for factors that were found by
Table 1 Countries/territories, intensive care units and patients included in the survey
No of
ICUs
No patients
surveyed
No patients given fluid
resuscitation
% patients given fluid
resuscitation
No episodes of fluid
resuscitation
Australia 24 402 142 35.3 346
Brazil 5 92 14 15.2 20
Canada 20 420 163 38.8 434
China 57 1,129 503 44.6 962
Denmark 17 133 65 48.9 146
France 42 583 110 18.9 214
Germany 23 535 253 47.3 675
Great Britain* 38 390 145 37.2 350
Hong Kong 6 95 46 48.4 109
Iceland 3 14 11 78.6 24
India 1 31 8 25.8 17
Ireland and N.
Ireland
8 94 29 30.9 70
Italy 71 514 158 30.7 297
Japan 5 47 17 36.2 28
New Zealand 9 104 36 34.6 148
Norway 19 112 46 41.1 88
Portugal 1 13 1 7.7 3
Saudi Arabia 4 78 26 33.3 57
Singapore 3 35 13 37.1 27
Sweden 24 177 71 40.1 189
Switzerland 6 77 38 49.4 118
United Arab
Emirates
1 17 6 35.3 16
USA 4 182 54 29.7 150
Total 391 5,274 1,955 37.1 4,488
*includes England, Scotland and Wales
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Figure 2 Percentage of fluid resuscitation episodes given as crystalloid, colloid or blood product according to country*. Crystalloid;
Colloid; Blood: *Difference in proportions given crystalloid, colloid or blood between countries, respectively P < 0.001, P < 0.001, P < 0.001
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administration of crystalloid, colloid or blood product,
significant associations remained (Table 5). The type of
fluid prescribed in the contributing ICUs differed signifi-
cantly between countries. Compared to Canada (where
the proportion of all fluid episodes prescribed as crystal-
loid, colloid and blood products was 35.5%, 40.6% and
28.3% respectively, and the distribution most closely
resembled that of all contributing ICUs combined) crys-
talloid was less likely to be administered to patients in
contributing ICUs in China, Great Britain and Sweden,
but more likely to be administered to patients in contri-
buting ICUs in Italy, New Zealand and the USA; there
was no significant difference in crystalloid prescription
to patients in contributing ICUs between Canada and
Australia, Denmark, France, Germany, Hong Kong and
Switzerland. Conversely, compared to Canada, colloid
was more likely to be administered to patients in contri-
buting ICUs in China and Great Britain and less likely
to be administered to patients in contributing ICUs in
New Zealand and the USA. Blood was significantly
more likely to be prescribed in contributing ICUs in
China, Denmark, Sweden and the USA compared to
contributing ICUs in Canada.
Other than country of location of the contributing
ICUs, few factors were independently associated with
the administration of crystalloid. Elective post-operative
patients were more likely to receive colloid than crystal-
loid (67.3% versus 38.5%). Compared to this group,
those admitted after emergency surgery or from the
emergency department were more likely to be resusci-
tated with crystalloid (OR = 1.57, 95% CI 1.12 to 2.20
and OR = 2.16, 95% CI 1.56 to 2.99 respectively).
Among the 514 patients who were admitted to the ICU
on the study day, colloid was also more commonly pre-
scribed than crystalloid (622/1,395 episodes (44.6%) ver-
sus 561/1,395 (40.2%)). Compared to this group, those
who had been in the ICU for longer were less likely to
receive crystalloid (OR = 0.70, 95% CI 0.56 to 0.87). In
patients where the indication for fluid was impaired per-
fusion or low cardiac output, colloid was administered
more commonly than crystalloid (899/1,743 (51.6%) ver-
sus 739/1,743 (42.4%)) and compared to this group, col-
loid was more likely to be administered as part of a unit
protocol (OR 1.65, 95% CI 1.21 to 2.25) and for correc-
tion of abnormal vital signs (OR 1.34, 95% CI 1.12 to
1.60). For episodes where the indication was anaemia,
bleeding or coagulopathy, administration of crystalloid
or colloid was less likely (OR = 0.15, 95% CI 0.12 to
0.20 and OR = 0.13, 95% CI 0.10 to 0.17 respectively)
and blood products more likely (OR = 26.7, 95% CI 20.2
to 35.4). The likelihood of receiving colloid increased
significantly with a lower mean arterial pressure (OR =
1.16, 95% CI 1.11 to 1.21 per 10 mmHg decrease).
The administration of blood products was predomi-
nantly determined by two factors, a reported indication
of ‘anaemia, bleeding or coagulopathy’ (OR 26.7, 95% CI
20.2 to 35.4 compared to ‘impaired perfusion or low
Figure 3 Type of colloid used as a percentage of all colloid episodes by country. Albumin; starch; gelatin; dextran
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1.24, 95% CI 1.18 to 1.30 per 10 g/L decrease). Patients
being treated with renal replacement therapy (OR 1.86,
95% CI 1.29 to 2.68) and with hyperlactaemia (OR 1.59,
95% CI 1.21 to 2.08) were also more likely to receive
blood products. Blood products were less likely to be
prescribed if the patient had severe sepsis diagnosed in
the 24 hours prior to the survey (OR 0.67, 95% CI 0.51
to 0.89). Compared to patients admitted to the ICU fol-
lowing elective surgery, blood was less likely to be pre-
scribed in those admitted from the hospital floor, the
operating theatre after emergency surgery or the emer-
gency room.
Discussion
In this large international study of fluid resuscitation in
ICUs we found that administration of resuscitation
fluids was very common. For patients who were sur-
veyed on their first day in the ICU, over half received
resuscitation fluid and overall more than a third of all
ICU patients received resuscitation fluid on the study
day. The main indications given for fluid resuscitation
were “impaired perfusion” or to “correct abnormal vital
signs”. Overall colloids were administered to more
patients and during more resuscitation episodes than
were crystalloids; the country in which the patient was
being treated was a major determinant of fluid choice
even after adjusting for patient and prescriber
characteristics.
This was a large pragmatic survey of the actual fluid
administered in intensive care. It covered a number of
ICUs from different countries and used standard data
collection forms and definitions. Detailed information
on many of the factors that may influence the choice of
fluid for resuscitation were recorded at the time that
fluid was given, allowing analyses to take into account
many potentially important patient and prescriber char-
acteristics. Our conclusions are limited by the fact that
we used a convenience sample, and the findings may
not be universally applicable. For instance, some regions,
such as Europe or Australasia, contributed greater num-
bers of patients to the study, and hence where findings
are reported for the entire population, they may more
accurately reflect practice in these regions. In addition,
we could not account for all possible factors that may
influence fluid prescription such as fluid that was pre-
scribed before the study day, nor could we adjust our
analyses for the individual practitioners or institutions.
A strength of our study is that we collected data on
fluids actually administered and related these to geo-
graphic, patient and prescriber characteristics. This
methodology is more reliable than previous studies that
have asked practitioners which fluids they prefer without
documenting actual use. Practitioner surveys conducted
in European countries [4,6] and Canada [5] suggest that
the fluid used for resuscitation varies substantially across
different countries and there is little consistency with
respect to preferred fluids for particular patient groups
or clinical scenarios. Our results show that the actual
fluids administered vary as much as clinicians’ stated
preferences.
This study was conducted in 2007 and we found that
in most countries colloids were used more commonly
than crystalloids. Preceding the study there was limited
evidence regarding appropriate indications for fluid
resuscitation [12,13]. The largest randomised controlled
trial had compared resuscitation with albumin or saline
in 6,997 critically ill patients; it reported no substantial
difference in any important patient-centred outcome
[14]. The Cochrane meta-analyses [2] current at the
time of our survey concluded that use of colloids was
hard to justify outside the context of a randomised con-
trolled trial. More recent evidence suggests that human
albumin increases mortality in patients with traumatic
Table 2 Characteristics of 1,955 patients who received
fluid resuscitation and indications for the 4,488 episodes
of fluid resuscitation
Demographic characteristics N = 1955
Age, yrs (mean, SD) 60.8 (17.4)
Sex (% male, N) 64.3
(1,256)
Admission characteristics
No of days in ICU at survey date (median, IQR) 3 (0, 10)
Hospital admission for trauma (%, N) 12.0 (234)
Sepsis in 24 hrs prior to survey date (%, N) 33.1 (642)
APACHE II in 24 hrs prior to survey date (mean, SD) 16.3 (8.5)
Died in ICU/hospital at ≤ 28 days (%, N) 16.1 (304)
Admission source
% Operating room after elective surgery 25.1 (489)
% Hospital floor 22.2 (432)
% Transfer from other ICU or hospital 11.8 (230)
% Operating room after emergency surgery 14.5 (283)
% Emergency room 17.0 (331)
% Hospital floor after previous ICU stay 9.4 (184)
Indication for fluid in each fluid resuscitation
episode
N = 4,488
% Impaired perfusion/low cardiac output (n) 39.2
(1,743)
% Abnormal vital signs 28.5
(1,266)
% Anaemia/bleeding/coagulopathy 18.5 (822)
% Unit protocol 6.6 (294)
% Other fluid losses 2.9 (131)
% Other 4.3 (191)
Percentages are calculated as column percents. Numbers do not necessarily
add to totals due to missing values.
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tions may increase the incidence of renal failure in
patients with severe sepsis [15,16]. Observational data
suggest that this risk might extend to use of other col-
loids [17].
In the face of emerging evidence that choice of resus-
citation fluid may affect important patient outcomes,
particularly in subgroups of critically ill patients, our
findings have important implications for clinicians,
researchers and policy makers. They suggest that many
clinicians are guided predominantly by local practice
and in many regions colloids are used widely and prefer-
entially for indications such as “unit protocol” or
“abnormal vital signs in the absence of impaired
Table 3 Characteristics of 1,955 study participants who received crystalloid, colloid or blood products (patients who
recevied more than one fluid type are included more than once)
Crystalloid Colloid Blood Products
Given
(N =
782)
Not
given
(N =
1,173)
P-
value*
Given
(N =
1,234)
Not
given
(N =
721)
P-
value
Given
(N =
717)
Not
given
(N =
1,238)
P-
value
Patient characteristic
Age, yrs (mean, SD) 60.3
(17.7)
61.2 (17.1) 0.3 61.7 (16.9) 59.3
(18.1)
0.003 60.0
(17.9)
61.3 (17.1) 0.09
Sex (% male, n) 64.3
(502)
64.3 (754) 0.99 64.6 (797) 63.7
(459)
0.7 64.2
(460)
64.4 (796) 0.9
Number of days in ICU at survey date (median, IQR) 1 (0,8) 4 (1,11) < 0.001 3 (0,10) 3 (0,11) 0.6 3 (1,10) 2 (0,10) 0.09
APACHE II score in 24 hrs prior to survey date (mean,
SD)
16.5
(8.7)
16.1 (8.4) 0.3 16.2 (8.6) 16.4 (8.4) 0.7 17.0
(8.7)
15.9 (8.4) 0.004
Patient characteristic: comparison of percentage of patients given or not given each fluid type who had the following characteristic
Hospital admission for trauma, n = 234% (N) 14.4
(112)
10.4 (122) 0.009 11.0 (135) 13.8 (99) 0.07 13.7 (98) 11.0 (136) 0.08
Hospital admission for trauma with brain injury, n =
81% (N)
5.2 (41) 3.4 (40) 0.05 3.8 (47) 4.7 (34) 0.3 4.9 (35) 3.7 (46) 0.2
Sepsis in 24 hrs prior to survey date, n = 642% (N) 27.8
(216)
36.6 (426) < 0.001 36.4 (445) 27.5
(197)
<
0.001
33.3
(237)
33.0 (405) 0.9
APACHE II in 24 hrs prior to survey date > 15, n =
957% (N)
49.6
(384)
49.7 (573) 0.96 48.4 (588) 51.9
(369)
0.1 54.2
(381)
47.1 (576) 0.003
APACHE II Chronic health points
Chronic health points liver criteria, n = 107% (N) 5.2 (40) 5.8 (67) 0.6 6.1 (74) 4.6 (33) 0.2 6.1 (43) 5.3 (64) 0.4
Chronic health points renal criteria, n = 88% (N) 4.4 (34) 4.7 (54) 0.8 4.0 (49) 5.5 (39) 0.1 5.5 (39) 4.0 (49) 0.1
Chronic health points cardiac criteria, n = 151%
(N)
7.8 (60) 7.9 (91) 0.96 8.4 (102) 6.9 (49) 0.2 7.9 (56) 7.8 (95) 0.9
Chronic health points respiratory criteria, n =
203% (N)
10.8 (83) 10.4 (120) 0.8 10.6 (128) 10.5 (75) 0.97 9.6 (68) 11.1 (135) 0.3
Chronic health points immunocompromised, n =
164% (N)
6.9 (53) 9.6 (111) 0.04 8.2 (100) 9.0 (64) 0.6 10.3 (73) 7.5 (91) 0.03
Admission source: comparison of percentage of patients from each source given or not given each fluid type
Admission source < 0.001 <
0.001
0.02
Operating room after elective surgery, n = 489% (N) 38.5
(188)
61.6 (301) 67.3 (329) 32.7
(160)
40.1
(196)
59.9 (293)
Hospital floor, n = 432% (N) 31.9
(138)
68.1 (294) 67.1 (290) 32.9
(142)
37.0
(160)
63.0 (272)
Transfer from other ICU or hospital, n = 230% (N) 38.3 (88) 61.7 (142) 57.8 (133) 42.2 (97) 38.7 (89) 61.3 (141)
Operating room after emergency surgery, n = 283%
(N)
43.8
(124)
56.2 (159) 67.8 (192) 32.2 (91) 35.3
(100)
64.7 (183)
Emergency room, n = 331% (N) 55.0
(182)
45.0 (149) 53.8 (178) 46.2
(153)
28.7 (95) 71.3 (236)
Hospital floor after previous ICU stay, n = 184% (N) 31.5 (58) 68.5 (126) 58.2 (107) 41.9 (77) 40.8 (75) 59.2 (109)
P-values highlighted where < 0.1 and hence eligible to be included in multivariate analysis.
*P-values calculated using chi2 for proportions, t-tests for means and Kruskal Wallis test for non-parametric data.
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to administration of crystalloid, colloid or blood by episode for 4,488 fluid resuscitation episodes in 1,955 study
participants
Crystalloid Colloid Blood
Given
N =
1,468
Not
given
N =
3,020
P-
value
Given
N =
2,173
Not
given
N =
2,315
P-
value
Given
N =
1,249
Not
given
N =
3,239
P-
value
Indication for fluid
Impaired perfusion or low cardiac output, n =
1,743% (N)
48.0 (739) 34.3
(1,004)
<
0.001
41.6 (899) 35.6 (844) <
0.001
27.0 (330) 42.7
(1,413)
<
0.001
Anaemia/bleeding/coagulopathy, n = 822% (N) 4.9 (68) 23.1 (754) 5.5 (119) 29.0 (703) 49.5 (717) 3.9 (105)
Other fluid losses, n = 131% (N) 3.4 (49) 2.8 (82) 2.9 (64) 3.1 (67) 2.3 (23) 3.2 (108)
Unit protocol, n = 294% (N) 5.9 (74) 8.2 (220) 9.9 (201) 4.9 (93) 3.8 (36) 8.7 (258)
Abnormal vital signs, n = 1,266% (N) 33.5 (483) 26.0 (783) 34.9 (751) 21.9 (515) 8.5 (100) 35.5
(1,166)
Other, n = 191% (N) 3.1 (44) 5.3 (147) 5.8 (117) 3.3 (74) 2.9 (32) 5.2 (159)
Fluid prescriber
ICU Specialist/consultant, n = 1,495% (N) 35.0 (482) 36.3
(1,013)
<
0.001
35.2 (690) 36.6 (805) 0.2 40.3 (486) 34.3
(1,009)
<
0.001
ICU Registrar, n = 1,368% (N) 27.1 (353) 31.7
(1,015)
30.9 (710) 29.6 (658) 30.2 (395) 30.3 (973)
ICU Resident/junior staff, n = 1,063% (N) 21.4 (431) 20.5 (632) 21.4 (497) 20.2 (566) 19.9 (235) 21.1 (828)
Other, n = 562% (N) 14.6 (202) 11.9 (360) 12.5 (276) 13.0 (286) 10.8 (133) 13.5 (429)
Cardiac failure SOFA < 3, n = 2,973%
(N)
0.1 0.08 0.2
SOFA 3+, n = 1,443%
(N)
25.6 (459) 27.9 (984) 27.6 (706) 26.6 (737) 28.0 (429) 26.8
(1014)
Respiratory failure SOFA < 3, n = 2,793%
(N)
0.01 0.02 0.1
SOFA 3+, n = 1,471%
(N)
31.4 (420) 34.6
(1,051)
34.7 (774) 32.4 (697) 34.8 (436) 33.2
(1035)
Renal replacement
therapy
No, n = 4,048% (N) 0.02 0.3 <
0.001
Yes, n = 417% (N) 8.7 (103) 10.2 (314) 9.5 (233) 10.1 (184) 10.9 (175) 9.3 (242)
Mechanical ventilation No, n = 1,568% (N) 0.04 0.1 0.02
Yes, n = 2,907% (N) 60.5 (910) 62.8
(1,997)
62.9
(1,438)
61.2
(1,469)
63.5 (845) 61.5
(2,062)
Low filling pressure** No, n = 1,448% (N) 0.001 0.8 0.1
Yes, n = 1,277% (N) 52.7 (430) 45.7 (847) 47.6 (652) 47.7 (625) 45.9 (331) 48.3 (946)
Metabolic acidosis** No, n = 3,062% (N) 0.02 0.7 0.9
Yes, n = 800% (N) 18.8 (279) 17.3 (521) 17.4 (372) 18.0 (428) 17.5 (243) 17.8 (557)
Lactate (mmol/L)** < 2, n = 1,851% (N) 0.3 0.6 0.07
2+, n = 1,222% (N) 37.0 (441) 36.5 (781) 36.9 (554) 36.5 (668) 37.2 (391) 36.5 (831)
Heart rate (mean, b/min) 95 94 0.07 94 94 0.8 93 94 0.9
Mean arterial pressure (mean, mmHg) 76 77 0.3 75 78 <
0.001
79 76 <
0.001
Haemoglobin (mean, g/L) 100 97 <
0.001
100 96 <
0.001
92 100 <
0.001
Creatinine (mean, umol/L) 148 142 0.06 141 147 0.002 146 143 0.2
Bilirubin** (mean, umol/L) 38 39 0.96 39 38 0.7 45 40 0.1
Albumin** (mean, g/L) 27 27 0.9 27 27 0.3 27 27 0.9
Urine output** (mean, ml/kg/hr) 2.0 1.8 0.1 1.8 1.8 0.99 2.0 1.8 0.02
Fluid output** (mean, ml/kg/hr) 2.9 2.8 0.9 2.8 2.8 0.6 3.1 2.7 0.008
P-values highlighted where < 0.1 and hence eligible to be included in multivariate analysis.
Proportions and means adjusted for repeated measures in individuals with more than one episode of fluid resuscitation. Proportions do not include missing
values. Numbers do not necessarily add to totals due to missing values.
**Variables have > 10% missing values
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episodes*
OR (95%CI) crystalloid
given
OR (95%CI) colloid
given
OR (95%CI) blood
given
Characteristic P-value P-value P-value
Age (per one year increase) 1.00 (0.99 to 1.00) 1.00 (1.00 to 1.01) 1.00 (0.99 to 1.01)
Study region
Canada 1.00 1.00 1.00
Australia 0.69 (0.42 to 1.11) 1.33 (0.88 to 2.02) 1.79 (1.00 to 3.23)
China 0.46 (0.30 to 0.69) < 0.001 1.72 (1.20 to 2.47) 0.003 3.33 (2.02 to 5.50) < 0.001
Denmark 0.50 (0.27 to 0.94) 1.43 (0.83 to 2.48) 4.09 (2.03 to 8.25) < 0.001
France 1.60 (0.96 to 2.66) 0.82 (0.51 to 1.32) 0.88 (0.43 to 1.78)
Germany 1.62 (1.08 to 2.44) 0.79 (0.54 to 1.14) 1.07 (0.62 to 1.84)
Great Britain 0.18 (0.10 to 0.32) < 0.001 4.72 (2.99 to 7.44) < 0.001 0.93 (0.51 to 1.73)
Hong Kong 0.88 (0.44 to 1.74) 0.93 (0.51 to 1.72) 1.17 (0.47 to 2.93)
Italy 2.06 (1.28 to 3.31) 0.003 1.33 (0.86 to 2.06) 1.10 (0.59 to 2.03)
New Zealand 3.43 (1.71 to 6.84) < 0.001 0.39 (0.21 to 0.74) 0.004 0.48 (0.19 to 1.24)
Sweden 0.43 (0.23 to 0.80) 0.008 1.67 (0.99 to 2.82) 4.99 (2.58 to 9.63) < 0.001
Switzerland 0.96 (0.48 to 1.92) 1.12 (0.60 to 2.10) 1.18 (0.49 to 2.82)
USA 2.55 (1.36 to 4.79) 0.004 0.16 (0.08 to 0.33) < 0.001 3.81 (1.78 to 8.17) 0.001
Other European 1.01 (0.59 to 1.72) 1.26 (0.77 to 2.05) 2.27 (1.17 to 4.39)
Other countries 2.52 (1.46 to 4.33) 0.001 0.53 (0.32 to 0.89) 1.43 (0.70 to 2.93)
Admission source
Operating room after elective
surgery
1.00 1.00 1.00
Hospital floor 1.26 (0.91 to 1.75) 1.05 (0.80 to 1.38) 0.59 (0.41 to 0.84) 0.003
Transfer from other ICU or hospital 1.49 (1.03 to 2.15) 0.80 (0.58 to 1.11) 0.60 (0.39 to 0.91)
Operating room after emergency
surgery
1.57 (1.12 to 2.20) 0.008 0.93 (0.69 to 1.24) 0.58 (0.39 to 0.86) 0.006
Emergency room 2.16 (1.56 to 2.99) < 0.001 0.67 (0.50 to 0.90) 0.008 0.50 (0.34 to 0.75) 0.001
Hospital floor after previous ICU stay 1.12 (0.75 to 1.67) 1.18 (0.83 to 1.67) 0.62 (0.39 to 0.99)
Trauma at hospital admission
No trauma 1.00 1.00 1.00
Trauma without brain injury 0.93 (0.64 to 1.35) 1.02 (0.73 to 1.42) 1.26 (0.82 to 1.95)
Trauma with brain injury 1.13 (0.69 to 1.84) 1.05 (0.68 to 1.64) 1.15 (0.63 to 2.08)
Sepsis in 24 hrs prior to survey date
No sepsis 1.00 1.00 1.00
Sepsis 0.90 (0.71 to 1.15) 1.26 (1.02 to 1.55) 0.67 (0.51 to 0.89) 0.005
Number of days in ICU at survey
date
0 days 1.00 1.00 1.00
> 0 days 0.70 (0.56 to 0.87) 0.001 1.28 (1.05 to 1.56) 0.91 (0.70 to 1.19)
Indication for fluid
Impaired perfusion or low cardiac
output
1.00 1.00 1.00
Anaemia/bleeding/coagulopathy 0.15 (0.12 to 0.20) < 0.001 0.13 (0.10 to 0.17) < 0.001 26.7 (20.2 to 35.4) < 0.001
Other fluid losses 0.90 (0.60 to 1.37) 0.83 (0.55 to 1.23) 0.90 (0.54 to 1.49)
Unit protocol 0.72 (0.52 to 1.01) 1.65 (1.21 to 2.25) 0.002 0.44 (0.29 to 0.67) < 0.001
Abnormal vital signs 0.93 (0.78 to 1.11) 1.34 (1.12 to 1.60) 0.001 0.34 (0.25 to 0.44) < 0.001
Other 0.39 (0.26 to 0.59) < 0.001 1.70 (1.18 to 2.45) 0.004 0.74 (0.47 to 1.18)
Fluid prescriber
ICU Specialist/consultant 1.00 1.00 1.00
ICU Registrar 0.88 (0.71 to 1.09) 1.10 (0.90 to 1.34) 0.83 (0.64 to 1.08)
ICU Resident/junior staff 1.19 (0.95 to 1.49) 1.04 (0.83 to 1.29) 0.72 (0.53 to 0.96)
Other 1.36 (1.05 to 1.76) 1.12 (0.87 to 1.45) 0.60 (0.42 to 0.85) 0.004
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episodes* (Continued)
Cardiovascular dysfunction
SOFA < 3 1.00 1.00 1.00
SOFA 3 to 4 0.94 (0.77 to 1.14) 1.08 (0.89 to 1.29) 1.26 (0.99 to 1.61)
Respiratory failure
SOFA < 3 1.00 1.00 1.00
SOFA 3 to 4 0.87 (0.72 to 1.06) 1.10 (0.92 to 1.33) 1.02 (0.80 to 1.31)
Renal replacement therapy
No 1.00 1.00 1.00
Yes 0.81 (0.59 to 1.11) 0.81 (0.60 to 1.08) 1.86 (1.29 to 2.68) 0.001
Mechanical ventilation
No 1.00 1.00 1.00
Yes 0.91 (0.75 to 1.12) 1.02 (0.85 to 1.23) 1.32 (1.02 to 1.71)
Low filling pressure
No 1.00 1.00 1.00
Yes 1.26 (1.02 to 1.55) 0.86 (0.70 to 1.05) 1.08 (0.83 to 1.40)
Heart rate (per 10 b/min increase) 1.05 (1.01 to 1.09) 0.98 (0.95 to 1.02) 1.01 (0.96 to 1.06)
Mean arterial pressure 0.97 (0.93 to 1.02) 1.16 (1.11 to 1.21) < 0.001 0.85 (0.80 to 0.91) < 0.001
(per 10 mmHg decrease)
Haemoglobin (per 10 g/L decrease) 0.97 (0.93 to 1.01) 0.94 (0.91 to 0.98) 0.004 1.24 (1.18 to 1.30) < 0.001
% 100+ 1.00 1.00 1.00
% 80 to 99 0.91 (0.75 to 1.10) 0.92 (0.77 to 1.10) 1.80 (1.39 to 2.31) < 0.001
% 70 to 79 0.72 (0.54 to 0.98) 0.89 (0.68 to 1.18) 3.24 (2.29 to 4.57) < 0.001
% < 70 0.75 (0.52 to 1.09) 0.60 (0.43 to 0.84) 0.004 5.74 (3.84 to 8.58) < 0.001
Creatinine
(per 10 umol/L increase) 1.00 (1.00 to 1.01) 1.00 (0.99 to 1.00) 1.00 (1.00 to 1.01)
< 170 umol/L 1.00 1.00 1.00
170+umol/L 0.86 (0.66 to 1.11) 1.00 (0.79 to 1.26) 1.22 (0.91 to 1.63)
Chronic health points immunocompromised
No 1.00 1.00 1.00
Yes 0.64 (0.44 to 0.93) 1.32 (0.96 to 1.83) 0.96 (0.64 to 1.45)
APACHE II 24 hrs prior to fluid administration
per 1 point increase in score 1.01 (1.00 to 1.03) 0.99 (0.98 to 1.01) 1.01 (0.99 to 1.02)
< 16 1.00 1.00 1.00
16+ 1.13 (0.91 to 1.41) 0.88 (0.72 to 1.07) 1.30 (1.00 to 1.68)
Lactate** (mmol/L)
< 2 1.00 1.00 1.00
2+ 1.02 (0.82 to 1.26) 0.90 (0.74 to 1.11) 1.59 (1.21 to 2.08) 0.001
Urine output** (ml/kg/hr)
per ml/kg/hr 1.03 (1.00 to 1.06) 1.03 (0.99 to 1.06) 0.98 (0.93 to 1.02)
< 0.5 1.00 1.00 1.00
0.5+ 0.89 (0.72 to 1.09) 1.10 (0.89 to 1.35) 1.03 (0.77 to 1.38)
Total fluid output** (ml/kg/hr)
per ml/kg/hr 1.01 (0.99 to 1.02) 1.01 (0.99 to 1.03) 1.01 (0.98 to 1.03)
< 1 1.00 1.00 1.00
1+ 1.17 (0.95 to 1.43) 1.03 (0.85 to 1.24) 1.02 (0.79 to 1.33)
P-values highlighted where < 0.01.
Analyses include 4,430 episodes and 1939 study participants as data were lost due to missing values which could not be included in the multivariate analysis
due to small numbers in cells. This number represents a loss of 1.5% of episodes and 1.1% of study participants.
**Variables have > 10% missing values.
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Page 10 of 12perfusion"; this has the potential to increase costs and to
harm some patients. Our results also imply that current
research evidence may not be considered robust enough
to override local custom and practice; those researching
in the field of fluid resuscitation should concentrate on
conducting randomised controlled trials of sufficient
size and methodological rigour to change clinical prac-
tice. Policy makers should be aware that practice varies
widely by country and is guided more by local practice
than by reliable research evidence. Given that pharma-
ceutical agents have to demonstrate safety and efficacy
before they receive marketing approval, regulatory agen-
cies should consider reviewing their criteria for granting
marketing approval to resuscitation fluids. In particular
they should require evidence from clinical trials that
examine longer term patient-centred safety and efficacy
outcomes.
It is possible that for many patients the choice of
resuscitation fluid does not significantly affect outcome.
If this is true, then the practice variation apparent in
our survey may be of academic and economic interest
only. However, as resuscitation fluids are administered
to so many critically ill adults each day, relatively small
differences in benefit, harm or cost per patient will
result in large effects overall. Further large-scale clinical
trials are needed both to examine the effects of particu-
lar fluids, and also to determine the appropriate indica-
tions for the administration of resuscitation fluids.
Conclusions
Fluid resuscitation is a common intervention in critically
ill patients. Recent evidence suggests that the use of col-
loids may be harmful in some subgroups of critically ill
patients but there are few reliable data about what fluids
patients receive and what factors influence fluid choice.
This study shows that the choice of fluid varies substan-
tially between ICUs and geographic location appears to
be a strong determinant of practice variation that is not
explained by patient factors. Despite evidence of super-
iority being lacking and increased cost, in this survey
colloids were more frequently administered to resusci-
tate critically ill patients than crystalloids.
Key messages
￿ Close to 40% of patients in intensive care units
receive resuscitation fluids each day.
￿ In this large international survey colloid resuscita-
tion fluids were used more often than crystalloids.
￿ The fluid used varies substantially between ICUs
and local practice rather than patient characteristics
appears to be the main factor in fluid choice.
Additional material
Additional file 1: Data collection forms: Case report form and other
data collection forms used in The SAFE TRIPS Study.
Additional file 2: Hierarchy for indications: Hierarchy of indications
for administration of resuscitation fluid. Were more than one
indication was given the indication highest on the hierarchy was
taken to be the main indication.
Additional file 3: The SAFE TRIPS Investigators: Listing of all SAFE
TRIPS investigators by country and institution.
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